14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Trends and projections of kidney cancer incidence at the global and national levels, 1990–2030: a Bayesian age-period-cohort modeling study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Identifying the temporal trends of kidney cancer (KC) incidence in both the past and the future at the global and national levels is critical for KC prevention.

          Methods

          We retrieved annual KC case data between 1990 and 2017 from the Global Burden of Disease (GBD) online database. The average annual percentage change (AAPC) was used to quantify the temporal trends of KC age-standardized incidence rates (ASRs) from 1990 to 2017. Bayesian age-period-cohort models were used to predict KC incidence through 2030.

          Results

          Worldwide, the number of newly diagnosed KC cases increased from 207.3 thousand in 1990 to 393.0 thousand in 2017. The KC ASR increased from 4.72 per 100,000 to 4.94 per 100,000 during the same period. Between 2018 and 2030, the number of KC cases is projected to increase further to 475.4 thousand (95% highest density interval [HDI] 423.9, 526.9). The KC ASR is predicted to decrease slightly to 4.46 per 100,000 (95% HDI 4.06, 4.86). A total of 90, 2, and 80 countries or territories are projected to experience increases, remain stable, and experience decreases in KC ASR between 2018 and 2030, respectively. In most developed countries, the KC incidence is forecasted to decrease irrespective of past trends. In most developing countries, the KC incidence is predicted to increase persistently through 2030.

          Conclusions

          KC incidence is predicted to decrease in the next decade, and this predicted decrease is mainly driven by the decreases in developed countries. More attention should be placed on developing countries.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Global Burden of Urologic Cancers, 1990-2013.

          Kidney, prostate, and bladder cancers increase with age and are influenced partly by modifiable risk factors. Urological cancer rates may increase substantially amid a growing, aging population.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis.

            The rising incidence of renal cell carcinoma (RCC) has been largely attributed to the increasing use of imaging procedures. Our aim was to examine stage-specific incidence, mortality, and survival trends of RCC in North America. We computed age-adjusted incidence, survival, and mortality rates using the Surveillance Epidemiology and End Results database. Between 1988 and 2006, 43,807 patients with histologically confirmed RCC were included. We calculated incidence, mortality, and 5-yr survival rates by year. Reported findings were stratified according to disease stage. Age-adjusted incidence rate of RCC rose from 7.6 per 100,000 person-years in 1988 to 11.7 in 2006 (estimated annual percentage change [EAPC]: +2.39%; p<0.001). Stage-specific age-adjusted incidence rates increased for localized stage: 3.8 in 1988 to 8.2 in 2006 (EAPC: +4.29%; p<0.001) and decreased during the same period for distant stage: 2.1 to 1.6 (EAPC: -0.57%; p=0.01). Stage-specific survival rates improved over time for localized stage but remained stable for regional and distant stages. Mortality rates varied significantly over the study period among localized stage, 1.3 in 1988 to 2.4 in 2006 (EAPC: +3.16%; p<0.001), and distant stage, 1.8 in 1988 to 1.6 in 2006 (EAPC: -0.53%; p=0.045). Better detailed staging information represents a main limitation of the study. The incidence rates of localized RCC increased rapidly, whereas those of distant RCC declined. Mortality rates significantly increased for localized stage and decreased for distant stage. Innovation in diagnosis and management of RCC remains necessary. Copyright © 2010 European Association of Urology. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Prediction of Cancer Incidence and Mortality in Korea, 2019

              Purpose This study aimed to report on cancer incidence and mortality for the year 2019 to estimate Korea’s current cancer burden. Materials and Methods Cancer incidence data from 1999 to 2016 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2017 were acquired from Statistics Korea. Cancer incidence and mortality were projected by fitting a linear regression model to observed age-specific cancer rates against observed years, then multiplying the projected age-specific rates by the age-specific population. The Joinpoint regression model was used to determine at which year the linear trend changed significantly; we used only the data of the latest trend. Results A total of 221,347 new cancer cases and 82,344 cancer deaths are expected to occur in Korea in 2019. The most common cancer sites thus far have been the lung, followed by the stomach, colon and rectum, breast, and liver. These five cancers represent half of the overall burden of cancer in Korea. For cancer associated mortality, the most common sites were lung, followed by the liver, colon and rectum, stomach, and pancreas. Conclusion The incidence rate of all cancer in Korea is estimated to decrease gradually. These up-todate estimates of the cancer burden in Korea could be an important resource for planning and evaluating cancer-control programs.
                Bookmark

                Author and article information

                Contributors
                chenqirj1567@163.com
                Journal
                Biomark Res
                Biomark Res
                Biomarker Research
                BioMed Central (London )
                2050-7771
                13 May 2020
                13 May 2020
                2020
                : 8
                : 16
                Affiliations
                [1 ]GRID grid.415869.7, Department of Urology, , Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, ; Shanghai, 200127 China
                [2 ]GRID grid.440171.7, Department of Urology, , Pudong New Area People’s Hospital, ; Shanghai, China
                [3 ]GRID grid.452847.8, Health Science Center, , Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, ; Shenzhen, 518020 China
                Article
                195
                10.1186/s40364-020-00195-3
                7222434
                32435498
                70c2fcf0-52e2-4b27-a58d-4f4145762c24
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 3 February 2020
                : 3 May 2020
                Categories
                Research
                Custom metadata
                © The Author(s) 2020

                kidney cancer,incidence,prediction,temporal trends,modeling study

                Comments

                Comment on this article